Centogene N.V.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNTG research report →
Companywww.centogene.com
Centogene N. V. , together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide.
- CEO
- Kim Stratton
- IPO
- 2019
- Employees
- 384
- HQ
- Rostock, DE
Price Chart
Valuation
- Market Cap
- $9.42M
- P/E
- -0.22
- P/S
- 0.17
- P/B
- -0.31
- EV/EBITDA
- -3.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 35.54%
- Op Margin
- -61.11%
- Net Margin
- -73.21%
- ROE
- 397.65%
- ROIC
- -47.95%
Growth & Income
- Revenue
- $48.54M · 2.24%
- Net Income
- $-35,532,000 · -11.59%
- EPS
- $-1.27 · -14.41%
- Op Income
- $-29,659,000
- FCF YoY
- -19.05%
Performance & Tape
- 52W High
- $0.43
- 52W Low
- $0.33
- 50D MA
- $0.16
- 200D MA
- $0.26
- Beta
- -0.67
- Avg Volume
- 431.57K
Get TickerSpark's AI analysis on CNTG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CNTG Coverage
We haven't published any research on CNTG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CNTG Report →